Enhancement of Antitumor Vaccination by Targeting Dendritic Cell-Related IL-10

Diana Llopiz1,2, Marta Ruiz1,2, Leyre Silva1,2 and Pablo Sarobe1,2*

1 Programa de Inmunología e Inmunoterapia, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain, 2 Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain

Understanding mechanisms associated to dendritic cell (DC) functions has allowed developing new antitumor therapeutic vaccination strategies. However, these vaccines have demonstrated limited clinical results. Although the low immunogenicity of tumor antigens used and the presence of tumor-associated suppressive factors may in part account for these results, intrinsic vaccine-related factors may also be involved. Vaccines modulate DC functions by inducing activating and inhibitory signals that determine ensuing T cell responses. In this mini review, we focus on IL-10, inhibitory cytokine induced in DC upon vaccination, which defines a suppressive cell subset, discussing its implications as a potential target in combined vaccination immunotherapies.

Keywords: antitumor therapeutic vaccination, dendritic cells, interleukin 10, immunosuppressive cells, PD-L1, type I IFN

DENDRITIC CELLS IN THERAPEUTIC VACCINATION

Since William Coley treated cancer patients with bacterial extracts to activate immunity, therapeutic vaccination has been considered a promising immunotherapeutic approach (1). During the last decades, we have witnessed the identification of dendritic cells (DC) as professional antigen presenting cells (2), characterization of their biological properties (3) and subsets (4), as well as the development of new techniques and tools to directly purify them (5) or differentiate from peripheral blood precursors (6). Therefore, a plethora of vaccination clinical trials has been carried out, either through in vivo administration of antigens and adjuvants, or ex vivo-prepared antigen-loaded DC (7, 8). Advances related to understanding those receptors and biological pathways involved in antigen capture and DC activation have allowed developing new vaccines, in terms of improving antigen targeting (9) or vaccine formulation (10), as well as improving direct DC isolation or differentiation from precursors, antigen loading and maturation (11). Despite these efforts in improving vaccine immunogenicity, those strategies reaching clinical phases, have provided limited clinical results (7). Accordingly, there is only a single licensed therapeutic cancer vaccine, Provenge, approved for castration resistant prostate cancer (12).

Characterization of the tumor microenvironment has clearly demonstrated the presence of immunosuppressive mechanisms which render T-cells dysfunctional (13, 14), partially accounting for vaccine failure. However, there are vaccine intrinsic factors which have not been fully elucidated and whose characterization may also explain in part these results. A variety of protocols have been used in vaccination clinical trials, with differences in parameters such as the type of antigens, its loading method in case of DC vaccines, the adjuvant or maturation protocol and the type/stage of disease and patients vaccinated, among others (15). This heterogeneity has made difficult to draw solid conclusions to identify those factors linking properties of vaccines with the ensuing immunological and clinical results (16).
Thus, although characterization of the vaccine product is usually a requisite for its release, commonly analyzed parameters, usually related to pro-immunogenic vaccine properties, have not completely revealed the relevant clues on vaccine immunogenicity (17).

Activation of naive T-cells by DC requires antigen recognition on MHC molecules, co-stimulatory signals and polarizing cytokines, according to the three-signal model (18). Although immature, resting DC usually lack these molecules, in the case of infections, contact with microbial pathogens leads to antigen capture and simultaneous sensing of pathogen associated molecular patterns (PAMPs), inducing thus the upregulation of genes involved in eliciting immunogenic responses (3). Similarly, in the tumor setting, danger associated molecular patterns (DAMPs) and other signals released by dying tumor cells are known to promote DC activation (19, 20). However, as in many biological processes, recognition of these signals by DC may also lead to upregulation of genes associated with negative feedback mechanisms, regulating thus immune activation. These include expression of membrane-bound co-inhibitory ligands (21, 22) that modulate signal 2, together with the release of soluble molecules (cytokines and metabolites) (23, 24) modulating signal 3. Vaccines rely either on the administration of antigens and immunostimulatory molecules (adjuvants) which will reach DC in vivo (25), or on administering DC that have been antigen-loaded and stimulated ex vivo (15). Similarly to infectious processes, DC may upregulate these control elements upon vaccine administration or during the DC preparation process (in the case of DC vaccines). Therefore, understanding these feedback mechanisms and delineation of optimized strategies to block them may allow developing more immunogenic vaccines. In this Minireview we will focus on IL-10, a cytokine regulating many functions, describing those mechanisms that control their induction on DC, its effect on these cells during vaccination as well as the rationale to best block their inhibitory effect with therapeutic vaccination purposes.

IL-10: AN INHIBITORY MOLECULE IN VACCINATION

Among cytokines reported to down-regulate the activation of antitumor immune responses, IL-10 plays a prominent role. IL-10 is a pleiotropic cytokine traditionally considered as immunosuppressive for antigen presenting cell functions and concomitant priming of T-cells (26). Although initially considered a cytokine produced by Th2 cells (27) or Tregs, it is now known that it is produced not only by other lymphocytic subsets, but also by cells of innate immunity, including DC and macrophages (28). Stimuli such as Toll-like receptor (TLR) ligands or CD40 ligand (CD40L), usually present in microbial pathogens or induced because of inflammation, have been included as adjuvants in different vaccination strategies (25). Although they have a high capacity to promote DC maturation and release pro-immunogenic cytokines like IL-12 (29), they may also induce IL-10, even with synergistic effects in some cases (30–32). There is an inverse relationship between IL-10 and IL-12 production by DC, which has been attributed to different mechanisms, including MAP kinase activation (33–35) and transcription factors NFIL3 (36) and DC-SCRIPT (37). Interestingly, DC-activating adjuvants have different cytokine-producing profiles, which may vary depending on the cytokine considered. Therefore, not all ligands have the same capacity to induce IL-10 (38), depending on the receptor involved and its associated signaling pathway. Indeed, although there are differences between murine and human studies because of the type of DC subsets and the corresponding TLR repertoire (39), some stimuli like TLR molecules (TLR2, TLR4, TLR7, or TLR9, among others) strongly induce IL-10 production (32, 40, 41). However, others like TLR3 ligand poly(IC) or CD40 agonists (CD40L or antiCD40 antibodies) are considered poorer IL-10 inducers, mainly when used alone (42, 43). DC receptors responsible for sensing microbial or endogenous inflammatory/danger signals can be grouped according to the mediator molecules and the corresponding signaling pathways used to induce DC activation (44). Most TLR ligands signal through MyD88, with the exception of TLR3, which relies on TRIF for signal transduction, and TLR4, which depends on MyD88- and TRIF-dependent pathways (45). Other non-TLR DC receptors, such as lectins receptors, Nod-like receptors or RIG-like receptors, use other sets of signaling molecules, including Syk, ASC and MAVS (46). Thus, signaling through MyD88 or Syk vs. signaling through TRIF (47) may explain the distinct capacity to produce IL-10 by different ligands. Furthermore, some of these pathways lead to the activation of different MAP kinases (p38, Jun, ERK, among others) that promote or inhibit IL-10 and IL-12 production, depending on the relative activation balance between kinases. In this respect, signaling pathways resulting in the activation of ERK (33–35) and MK2 (48) have been shown to induce IL-10. In addition, the receptor and signaling pathway not only determine IL-10 production, but also the susceptibility of DC to autoimmune effects mediated by its own IL-10. It has been demonstrated that IL-10 induced in DC after stimulation by ligands that signal through the MyD88 pathway (e.g., TLR4 or TLR9 ligands), inhibits DC functions, such as the secretion of cytokines IL-6 and IL-1β and expression of IL-12 p35, IL-23 p19, TNF-α, and IFN-β mRNA (49). In contrast, IL-10 induced by curdlan (a Dectin-1 ligand) does not affect DC functions. Finally, IL-10 receptor expression may also represent an additional control mechanism. Surface expression of IL-10 receptor is downregulated upon LPS-induced maturation (50), potentially explaining the increased susceptibility of immature vs. mature DC to IL-10 inhibitory effects. All these results suggest that there is an intricate network of interactions involving pathways regulating IL-10 production as well as those implicated in the susceptibility to its effects, which has to be considered when analyzing the role of IL-10 during DC activation.

IL-10 has been described in many cancer patients as a poor prognostic factor (51–54). It can be detected in serum (52, 53) and in the tumor (51), produced by tumor cells (55, 56) as well as by infiltrating hematopoietic cells, including myeloid (57) and lymphocytic subsets (58–61). Although IL-10 has an inhibitory
impact for antigen presenting cells, contradictory effects have been reported in the case of antitumor T-cells (62–64). In this regard, it has been demonstrated that IL-10 increases functional properties of already activated effector CD8 T-cells. In fact, in different murine tumor models, including mammary carcinoma, skin squamous carcinoma, and several transplantable models, such as breast, colon, and melanoma tumors, administration of IL-10 inhibits tumor growth, promoting antitumor functions of effector T-cells, increasing tumor infiltration, IFN-gamma production and lytic molecules (65, 66). However, regarding priming of naive T-cells during initial stages, IL-10 has been considered detrimental. This is due to its inhibitory role on antigen presenting cells at different levels, such as migration (67), expression of co-stimulatory molecules (68), production of Th1 polarizing cytokines (57, 69) and blocking cross-priming and priming with low-affinity peptides of a self/tumor-antigen and concomitant T-cell activation (70). Therefore, to consider IL-10 as a target in tumor immunotherapy, the immunological context has to be taken into account. In those settings where already primed effector cells exist, IL-10 may potentiate their properties (65, 66). However, if T-cell priming or generation of an antitumor immune response is needed, as in vaccination, therapeutic benefit would be achieved by IL-10 blockade. Indeed, preclinical data regarding IL-10 blockade has demonstrated an enhancement of vaccine immunogenicity, not only in the cancer setting (43, 71, 72) but also in other models (41, 73, 74). Although, as previously mentioned, IL-10 can be expressed by different cell subsets, we and others (43, 75) have demonstrated that antigen presenting cell-derived IL-10 down-regulates the elicitation of Th1 responses. Indeed, vaccine-dependent induction of IFN-gamma-producing T-cells is greatly enhanced by IL-10 blockade when using adjuvants promoting IL-10 production by DC (75), which in the case of tumors results in a stronger therapeutic effect (43). Thus, although different IL-10 sources coexist in the tumor setting, DC-derived IL-10 seems to determine vaccination efficacy.

There are no mechanistic experiments in the vaccination setting explaining the presence of different DC populations according to their IL-10 production. Indeed, it is not known whether the vaccine generates both types of DC from different precursors or the same DC subset may behave differently. However, in the viral model it has been demonstrated that, whereas IL-10- DC are originated from conventional DC precursors, the source of IL-10+ DC are monocytes differentiated as a consequence of inflammatory mediators, which are subsequently endowed with suppressive properties by type I IFN (78). This association between IL-10 production by DC and the presence of type I IFN, is in agreement with the vaccine setting, where many adjuvants known to induce IL-10 (ligands of TLR4, TLR7, and TLR9) also induce type I IFN (79), a cytokine that determines IL-10 levels (80). Moreover, IL-10+ DC have higher ISG expression, indicating a stronger response to type I IFN. IL-10 and type I IFN production have been linked as regulatory mechanisms, and blockade of IFN signal leads to a diminished IL-10 expression (81, 82). However, there may be additional factors behind IL-10 induction, since potent type I IFN inducers, such as the TLR3 ligand poly(I:C), are poor at inducing IL-10. Similarly, expression of other inhibitory molecules, such as PD-L1, also depends on type I IFN, in agreement with the pivotal role of this cytokine in generating the immunosuppressive effect on this DC subpopulation (81, 82). Interestingly, in addition to these immunoregulatory effects, it has been reported that type I IFN is required by DC to induce rejection of immunogenic tumors, supporting the induction of adaptive responses (83). Moreover, efficacy of therapeutic strategies such as vaccines (84) or other approaches relying on cross-presentation of tumor antigens by DC (85) also depends on type I IFN. Overall, these results suggest that type I IFN plays a dual role on DC-mediated tumor immunity, by promoting the generation of antitumor responses, but at the same time inducing regulatory mechanisms -including IL-10- to balance the magnitude of these responses (86).

In addition to the murine setting, there are several examples of suppressive DC in human studies, having in common the production of IL-10. Besides those protocols aimed at preparing tolerogenic DC by incubation with IL-10 in the therapy of autoimmune diseases, which are not the scope of this Minireview, there are also inflammatory conditions where induction of IL-10 takes place and results in similar suppressive functions. As an example, in vitro differentiation of monocytes in an inflammatory environment, such as the presence of TLR ligands (e.g., LPS or R848), led to generation of tolerogenic CD14+ DC expressing high IL-10 and PD-L1 levels (87) in a STAT3-dependent manner. Moreover, combined DC stimulation with potent TLR ligands results in partial inhibition, due to IL-10 induced by some of these compounds (42). More interestingly, the relevance of vaccine-derived IL-10 has been also demonstrated in the clinical setting. A recent paper (88) analyzing properties of monocye-derived DC used as vaccines in prostate cancer patients reported that IL-10, in addition to CD14, and MCP-1 and MDC chemokines, identified a gene signature that could discriminate between patients responding or not to the vaccine. Authors found that

**IL-10 AS A MARKER OF SUPPRESSIVE DC**

IL-10 production by DC not only affects their functional properties, but also identifies a subpopulation characterized by many immunosuppressive features, both at the phenotypical and functional levels. Mice vaccinated with IL-10-inducing adjuvants have an IL-10-producing DC subset (from now on IL-10+ DC), which is almost absent in unvaccinated mice. IL-10+ DC are characterized by poorer expression of co-stimulatory molecules and inflammatory cytokines, as well as upregulation of co-inhibitory ligands such as PD-L1, resulting thus in a cell population with much lower T-cell stimulatory capability (76) (Figure 1). Interestingly, in addition to their low antigen presenting capacity, IL-10+ DC also suppress antigen presentation by third-party cells, reinforcing their inhibitory role. Some of these features of IL-10+ DC have been also observed in persistent viral infection models (77), suggesting that generation of this DC subset may not be specific of vaccines and operates in other settings.
Targeting IL-10 for Antitumor Vaccination

FIGURE 1 | Vaccine-induced IL-10 production defines two different dendritic cell populations. Adjuvants included in vaccines promote the generation of two DC populations identified by their capacity to produce IL-10. IL-10+ DC are characterized by poorer expression of MHC and co-stimulatory molecules, upregulation of PD-L1 and immunosuppressive cytokines, resulting in impaired ability to activate antitumor T cells, as opposed to IL-10− DC, which retain full capacity to trigger functional antitumor T cell responses. Moreover, IL-10+ DC inhibit antigen-presenting functions of IL-10− DC.

clinical and strong immunological responses correlated with low expression of molecules belonging to this gene signature, some of them, like CD14 and IL-10, already described as tolerogenic markers of DC. In addition to monocyte-derived DC, vaccines based on DC directly isolated from blood have been also used. When analyzing the cell composition of these vaccines, Bakdash et al. found a BDCA1+ DC population positive for CD14, which is elevated in patients as compared with healthy donors (89). These cells are a DC subset that, although overlaps in many factors with monocytes and classical BDCA1+ DC, can be considered as a distinct population, characterized by displaying suppressive properties. Therefore, they have been suggested as responsible for hampering vaccine efficacy in patients. Interestingly, besides CD14 expression [as in DC previously mentioned (88)], these DC are characterized by stronger IL-10 secretion than monocytes or classical BDCA1+ DC, can be considered as a distinct population, characterized by displaying suppressive properties. Therefore, they have been suggested as responsible for hampering vaccine efficacy in patients. Interestingly, besides CD14 expression [as in DC previously mentioned (88)], these DC are characterized by stronger IL-10 secretion than monocytes or classical BDCA1+ DC upon LPS stimulation, reagent also used to induce DC maturation in (88). Also in the clinical setting, we reported results from a vaccination pilot clinical trial of patients suffering from chronic hepatitis C by using a DC vaccine (90). Poor Th1 immune responses were detected in vaccinated patients. Although disease status could have played a role in these results, we detected higher levels of CD14+ DC and a stronger IL-10 production by the DC vaccine prepared from patients, as opposed to DC obtained from healthy individuals, in agreement with aforementioned clinical studies. Interestingly, blockade of IL-10 during vaccine preparation restored in vitro production of Th1 responses in these patients, suggesting again a relevant role of IL-10 in vaccine efficacy.

Therefore, considering the relevance of IL-10 during therapeutic vaccination, different blockade strategies have been used, depending on the type of vaccine. As summarized in Table 1, for those vaccines relying on direct antigen administration, antibodies blocking IL-10 or IL-10R have been used in most cases. When using DC administration, in addition to direct IL-10/IL-10R blockade, genetic ablation of IL-10/IL-10R expression and pharmacological inhibition of pathways leading to IL-10 production have been also used. Despite these different options in preclinical studies, only antibodies against IL-10, in combination with a TLR9 ligand, have advanced to clinical phases for the treatment of patients with advanced malignancies.

In addition to IL-10 as a target, description of this IL-10+ DC subset and its immunosuppressive properties allows the identification of other relevant molecular mechanisms involved in their inhibitory effect. Therefore, these molecules could be potentially amenable to modulation as a strategy to enhance vaccine potency. Among them, PD-L1 is an interesting upregulated target, since there are already approved therapies directed at this pathway (102). By using samples from patients with different types of tumors (hepatocellular carcinoma and glioblastoma, among others), it has been demonstrated that PD-L1 expression is regulated by IL-10 (103, 104). However, in our hands in vaccination experiments in murine models, combination of vaccine with IL-10 blockade did not modify PD-L1 expression on DC, despite a decrease in the percentage of IL-10+ DC (76), pointing at PD-L1 as an independent target and providing an additional opportunity
TABLE 1 | Strategies aimed at blocking IL-10 for combination with antitumor vaccines.

| IL-10 blocking strategy | Vaccine | Tumor | Reference |
|-------------------------|---------|-------|-----------|
| **PRECLINICAL**         |         |       |           |
| Anti-IL-10 antibodies   | Plasmid encoding MIP3α-hgp100 | B16F10 | (91) |
|                        | DC pulsed with gp100 peptide | B16F10 | (92) |
|                        | DC pulsed with tumor cells | MC38 | (93) |
| Anti-IL-10R antibodies | OVA + imiquimod | B16-OVA | (43) |
|                        | HPV E7 peptide + LPS | TC-1 | (72) |
| Soluble IL-10R          | DC pulsed with tumor cells | B16F10 | (94) |
| siRNA targeting IL-10   | DC pulsed with E7 peptide | TC-1 | (95) |
|                        | DC pulsed with E7 peptide | TC-1 | (96) |
| shRNA targeting IL-10   | DC pulsed with MART-1 peptide | Human melanoma (in vitro) | (97) |
| Inhibitors of IL-10-inducing pathways: |         |       |           |
| p38 MAPK inhibitor      | DC pulsed with tumor cells | B16F10 | (100) |
| COX2 inhibitor          | DC pulsed with tumor cells | B16F10 | (100) |
| Retinoic acid receptor alpha inhibitor | DC pulsed with tumor cells | B16F10 | (101) |
| **CLINICAL**            |         |       |           |
| Anti-IL-10 antibodies   | TLR9 ligand | Advanced tumors | clinicaltrials.gov NCT02731742 |

for DC modulation. Accordingly, combined blockade of IL-10 and PD1/PD-L1 clearly potentiated vaccine immunogenicity, resulting in a greater therapeutic antitumor effect (76, 84). These results are in agreement with equivalent experiments carried out in viral models in vitro (105) and in vivo (106). In addition to these two important suppressive pathways, other inhibitory molecules, including enzymes (IDO) (77), cytokines (TGF-beta), ligands for receptors found on T-cells (HVEM) or inhibitory intracellular molecules (IRAK-3) (78), have been described in this IL-10+ DC subset. Co-expression of these negative factors has been already reported in other examples of DC with poor stimulatory capacity (107, 108), indicating that they are commonly operating in settings where T-cell responses are not fully activated, and suggesting that combined blockade of these mechanisms may improve DC functions, with special relevance in vaccination protocols.

CONCLUSION AND FUTURE DIRECTIONS

Different immunosuppressive elements present at the tumor microenvironment have been described, demonstrating that they may hamper effector functions of tumor-infiltrating lymphocytes. These mechanisms would partially account for the limited effect of therapeutic vaccines, suggesting that combination therapies that include vaccines plus blockade of these elements may increase their efficacy. However, together with these elements, additional inhibitory pathways induced by the vaccine are triggered. Many of them, such as IL-10 production, exert their effects at the level of DC, by impairing their antigen presenting functions and negatively regulating T-cell activation. Some of the already identified vaccine-induced suppressive elements present in IL-10+ DC, are common to those operating at the tumor level, allowing the design of new combinatorial vaccination strategies based on drugs currently approved or in development. Therefore, future vaccination strategies, besides highly immunogenic and properly formulated and adjuvanted antigens, should incorporate blockade of IL-10 and additional inhibitory elements, enhancing thus vaccine potency and associated therapeutic efficacy.

AUTHOR CONTRIBUTIONS

DL and PS conceived, wrote the manuscript and did the figures. MR and LS contributed to manuscript editing and final revision.

FUNDING

This work is funded by grants from Ministerio de Economía y Competitividad/Instituto de Salud Carlos III (PI14/00343; PI17/00249), Fundación Bancaria La Caixa-Hepacare Project and Murchante Contra el Cáncer to PS.

ACKNOWLEDGMENTS

We thank Drs. J.J. Lasarte and S. Hervás-Stubbs for their helpful discussion and critical reading of the manuscript.
39. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol. (2004) 5:987–95. doi: 10.1038/ni1112

40. Iang S, Uematsu S, Akira S, Salgale P. IL-6 and IL-10 induction from dendritic cells in response to Mycobacterium tuberculosis is predominantly dependent on TLR2-mediated recognition. J. Immunol. (2004) 173:3392–7. doi: 10.4049/jimmunol.173.5.3392

41. Castro AG, Neighbors M, Hurst SD, Zonin F, Silva RA, Murphy E, et al. Anti-interleukin 10 receptor monoclonal antibody is an adjuvant for T helper cell type 1 responses to soluble antigen only in the presence of lipopolysaccharide. J. Exp. Med. (2000) 192:1529–34. doi: 10.1084/jem.192.2.151529

42. Bogunovic D, Manches O, Godefroy E, Yewdall A, Gallois A, Thierry-Mieg D, et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of patients with nasopharyngeal carcinoma. Int J Cancer (2015) 136:2379–86. doi: 10.1002/ijc.29394

43. Llopiz D, Aranda F, Diaz-Valdes N, Ruiz M, Infante S, Belsue V, et al. Interleukin-10 and its role in mediating dendritic cell-mediated immune responses. Cell Immunol. (2014) 342:1–15. doi: 10.1016/j.cellimm.2014.06.003

44. Brubaker SW, Bonham KS, Zanoni I, Kagan JC. Innate immune recognition of Trypanosoma cruzi: a cell biological perspective. Trends Immunol. (2003) 24:36–43. doi: 10.1016/S1471-4906(02)00009-1

45. Aksenov AA, Castro AG, Neighbors M, Hurst SD, Zonin F, Silva RA, Murphy E, et al. Syk-dependent ERK activation regulates IL-2 and IL-10 production by human carcinoma cell lines and its implications for thi cell differentiation and autoimmune encephalomyelitis. J. Immunol. (1999) 163:2770–80. doi: 10.4049/jimmunol.163.5.2770

46. Corinti S, Albanesi C, la Sala A, Pastore S, Girolomoni G. Regulatory activity of interleukin-10 predicts clinical outcome in patients with nasopharyngeal carcinoma. Cancer Res. (2002) 62:6654–60. doi: 10.1158/0008-5472.CAN-01-2678

47. Slack EC, Robinson MJ, Hernanz-Falcon P, Brown GD, Williams DL, Bolen H, et al. Staining of interleukin-10 predicts clinical outcome in patients with Hodgkin's disease. J. Exp. Med. (2003) 197:513–24. doi: 10.1084/jem.197.3.513

48. Groux H, Bigler M, de Vries JF, Roncarolo MG, Influenza and dietary entry effects of IL-10 on human CD8+ T cells. J. Immunol. (2000) 164:3188–93. doi: 10.4049/jimmunol.164.6.3188

49. Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM. The dual role of IL-10. Trends Immunol. (2003) 24:36–43. doi: 10.1016/S1471-4906(02)00009-1

50. Shalapour S, Lin XJ, Bastian IN, Brain J, Burt AD, Aksenov AA, et al. The MAPK-activated kinase MK2 attenuates dendritic cell-mediated Th1 differentiation and autoimmunity. Eur J Immunol. (2005) 35:2678–86. doi: 10.1002/eji.2005302942

51. Mumm JB, Emmerich M, Zhang X, Chan I, Wu L, Mauze S, et al. IL-10 promotes homeostatic proliferation of human CD8+ memory T cells and can be overcome by IL-10 blockade. J. Immunol. (2010) 185:2360–6. doi: 10.4049/jimmunol.1000610

52. Ding I, Linsley PS, Huang YL, Germain RN, Shevach EM. IL-10 inhibits macrophage costimulation activity by selectively inhibiting the up-regulation of B7 expression. J. Immunol. (1993) 151:12244–5. doi: 10.4049/jimmunol.151.6.12244

53. D’Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J. Exp. Med. (1993) 178:1041–8. doi: 10.1084/jem.178.3.1041

54. Nizzioli G, Larghi P, Paroni M, Crosti MC, Moro M, Nedermann H, et al. IL-10 promotes homeostatic proliferation of human CD8+ memory T cells and, when produced by CD11c(+) DCs, shapes naive CD8(+) T-cell priming. Eur J Immunol. (2016) 46:1622–32. doi: 10.1002/eji.201546136

55. Liu H, Wagner WM, Gao E, Yang Y, Yuan D, Amon LM, et al. Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade. J. Immunol. (2010) 184:5360–7. doi: 10.4049/jimmunol.0902997

56. Chen S, Wang X, Wu X, Wei MQ, Zhang B, Liu X, et al. IL-10 signalling blockade at the time of immunization inhibits Human papillomavirus 16 E7 transformed TC-1 tumour cells growth in mice. Cell Immunol. (2014) 290:145–51. doi: 10.1016/j.cellimm.2014.06.002

57. Brooks DG, Lee AM, Elsaesser H, McGavern DB, Oldstone MB. IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection. J. Exp. Med. (2008) 209:533–41. doi: 10.1084/jem.20071948

58. Bai F, Town T, Qian F, Wang P, Kamanaka M, Connolly TM, et al. IL-10 signaling blockade controls murine West Nile virus infection. PLoS Pathog. (2009) 5:e1000610. doi: 10.1371/journal.ppat.1000610
75. Darrah PA, Hegde ST, Patel DT, Lindsay RW, Chen L, Roederer M, et al. IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform. *J Exp Med.* (2010) 207:1421–33. doi: 10.1084/jem.20092532

76. Llopiz D, Ruiz M, Infante S, Villanueva L, Silva L, Hervas-Stubbs S, et al. IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination. *Oncotarget* (2017) 8:2659–71. doi: 10.18632/oncotarget.13736

77. Wilson EB, Kidani Y, Elsasser H, Barnard J, Ralf L, Karp CL, et al. Emergence of distinct multiarmed immunoregulatory antigen-presenting cells during persistent viral infection. *Cell Host Microbe* (2012) 11:481–91. doi: 10.1016/j.chom.2012.03.009

78. Cunningham CR, Champhekar A, Tullius MV, Dillon BJ, Zhen A, de la Fuente JR, et al. Type I, and Type II interferon coordinately regulate suppressive dendritic cell fate and function during viral persistence. *PloS Pathog* (2016) 12:e1005356. doi: 10.1371/journal.ppat.1005356

79. Noppert SJ, Fitzgerald KA, Hertzog PJ. The role of type I interferons in TLR responses. *Immunol Cell Biol.* (2007) 85:446–57. doi: 10.1038/sj.icb.7100999

80. Howes A, Taubert C, Blankley S, Spink N, Wu X, Graham CM, et al. Differential production of type I IFN determines the reciprocal levels of IL-10 and proinflammatory cytokines produced by C57BL/6 and BALB/c macrophages. *J Immunol.* (2016) 197:2388–53. doi: 10.4049/jimmunol.1501923

81. Wilson EB, Yamada DH, Elsasser H, Herskovitz J, Deng J, Cheng G, et al. Blockade of chronic type I interferon signaling to control persistent LCMI infection. *Science* (2013) 340:202–7. doi: 10.1126/science.1235208

82. Teijaro JR, Ng C, Lee AM, Sullivan BM, Sheehan KC, Welch M, et al. Persistent LCMI infection is controlled by blockade of type I interferon signaling. *Science* (2013) 340:207–11. doi: 10.1126/science.1235214

83. Diamond MS, Kinder M, Matsuhashi H, Mashayekhi M, Dunn GP, Archambault JM, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. *J Exp Med.* (2011) 208:1989–2003. doi: 10.1084/jem.20101158

84. Villanueva L, Silva L, Llopiz D, Ruiz M, Iglesias T, Lozano T, et al. The Toll like receptor 4 ligand cold-inducible RNA-binding protein as a vaccine platform against cancer. *Immunol Cell Biol.* (2013) 91:1421–33. doi: 10.1084/jem.201040979

85. Rossowska J, Anger N, Kiciodzińska J, Paijais-Piasceka E, Bielawksa-Pohl A, Wojas-Turek J, et al. Temporary elimination of IL-10 enhanced the effectiveness of cyclophosphamide and BMDC-based therapy by decrease of the suppressor activity of MDCSs and activation of antitumour immune response. *Immunobiology* (2015) 220:389–98. doi: 10.1016/j.imbio.2014.10.009

86. Marchi LH, Paschoalin T, Travassos LR, Rodrigues EG. Gene therapy with interleukin-10 receptor and interleukin-12 induces a protective interferon-gamma-dependent response against B16F10-Nex2 melanoma. *Cancer Gene Ther.* (2010) 18:110–22. doi: 10.1038/cgt.2010.58

87. Kim JH, Kang TH, Nob KH, Bae HC, Ahn YH, Lee YH, et al. Blocking the immunosuppressive axis with small interfering RNA targeting interleukin (IL)-10 receptor enhances dendritic cell-based vaccine potency. *Clin Exp Immunol.* (2011) 165:180–9. doi: 10.1111/j.1365-2249.2011.04410.x

88. Ahn YH, Hong SO, Kim JH, Noh KH, Song KH, Lee YH, et al. The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor-beta receptor on dendritic cells potentiates tumour antigen-specific CD8(+) T cell immunity. *Clin Exp Immunol.* (2015) 181:164–78. doi: 10.1111/cei.12620

89. Chhabra A, Chakraborty NG, Mukherji B. Silencing of endogenous IL-10 in human dendritic cells leads to the generation of an improved CTL response against human melanoma associated antigenic epitope, MART-1 27-35. *Clin Immunol.* (2008) 126:251–9. doi: 10.1111/j.1529-0131.2007.11011.x

90. Rossowska J, Anger N, Szczypa-Giel A, Mierzewska J, Paijais-Piasceka E. Reprogramming the murine colon cancer microenvironment using lentivectors encoding shRNA against IL-10 as a component of a potent DC-based chemoinmunotherapy. *J Exp Clin Cancer Res.* (2018) 37:126. doi: 10.1186/s13048-018-0799-y

91. Berezhnoy A, Stewart CA, McNamara JO, 2nd, Thiel W, Giangrande P, Trinchieri G, et al. Isolation and optimization of murine IL-10 receptor blocking oligonucleotide aptamers using high-throughput sequencing. *Mol Ther.* (2012) 20:1242–50. doi: 10.1038/mt.2012.18

92. Jarnicki AG, Conroy H, Breerton C, Donnelly G, Toomey D, Walsh K, et al. Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. *J Immunol.* (2008) 180:3797–806. doi: 10.4049/immunol.180.6.3797

93. Galvin KC, Dyck L, Marshall NA, Stefanska AM, Walsh KP, Moran B, et al. Blocking retinoic acid receptor-alpha enhances the efficacy of a dendritic cell vaccine against tumours by suppressing the induction of regulatory T cells. *Cancer Immunol Immunother.* (2013) 62:1273–82. doi: 10.1007/s00262-013-1432-8

94. Gong J, Chehrazi-Raffle A, Reddy S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. *J Immunother Cancer* (2018) 6:8. doi: 10.1186/s40425-018-0316-z

95. Wu K, Kryczek I, Chen L, Zou W, Welling TH. Kupffer cell suppression through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. *J Immunol.* (2008) 180:3797–806. doi: 10.4049/immunol.180.6.3797

96. Bloch O, Crane CA, Kaur R, Saafae M, Rutkowski MJ, Parsa AT. Glomias promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. *Clin Cancer Res.* (2013) 19:3165–75. doi: 10.1158/1078-0432.CCR-12-3314

97. Porichis F, Hart MG, Zupkosky J, Barblu L, Kwon DS, McMullen A, et al. Differential impact of PD-1 and/or interleukin-10 blockade on HIV-1-specific CD8+ T cell and antigen-presenting cell responses. *Front Immunol.* (2018) 9:1923.
cell functions. *J Virol.* (2014) 88:2508–18. doi: 10.1128/JVI.02034-13

106. Brooks DG, Ha SJ, Elsaesser H, Sharpe AH, Freeman GJ, Oldstone MB. IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. *Proc Natl Acad Sci USA.* (2008) 105:20428–33. doi: 10.1073/pnas.0811139106

107. Gordon JR, Li F, Nayyar A, Xiang J, Zhang X. CD8 \( \alpha^+ \), but not CD8 \( \alpha^- \), dendritic cells tolerize Th2 responses via contact-dependent and -independent mechanisms, and reverse airway hyperresponsiveness, Th2, and eosinophil responses in a mouse model of asthma. *J Immunol.* (2005) 175:1516–22. doi: 10.4049/jimmunol.175.3.1516

108. Han Y, Chen Z, Yang Y, Jiang Z, Gu Y, Liu Y, et al. Human CD14\(^+\) CTLA-4\(^+\) regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-

dioxygenase production in hepatocellular carcinoma. *Hepatology* (2014) 59:567–79. doi: 10.1002/hep.26694

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Llopiz, Ruiz, Silva and Sarobe. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.